• Home
  •  / Pressure BioSciences

Pressure BioSciences

OverviewSuggest Edit

Pressure BioSciences, Inc. (PBI), a life sciences company, engages in the research, development, and commercialization of sample preparation system. It focuses on the development of a platform technology, called pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The Company offers Barocycler instrument and an internally developed disposable PULSE (Pressure Used to Lyse Samples for Extraction) Tubes, which together make up the PCT sample preparation system.

TypePublic
Founded2004
HQEaston, MA, USMap
Websitepressurebiosciences.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)17(+22%)
Revenue (FY, 2019)$1.8 M(-26%)
Share Price (Feb 2021)$2.3 (-7%)
Cybersecurity ratingCMore

Key People/Management at Pressure BioSciences

Richard T. Schumacher

Richard T. Schumacher

President, Chief Executive Officer and Director
Jeffrey N. Peterson

Jeffrey N. Peterson

Chairman of the Board
Edmund Ting

Edmund Ting

Senior Vice President of Engineering
Vito J. Mangiardi

Vito J. Mangiardi

Director
Kevin A. Pollack

Kevin A. Pollack

Director
Michael S. Urdea

Michael S. Urdea

Director
Show more

Pressure BioSciences Office Locations

Pressure BioSciences has offices in Easton and Medford
Easton, MA, US (HQ)
14 Norfolk Ave, South Easton
Medford, MA, US
200 Boston Ave #1950
Show all (2)

Pressure BioSciences Financials and Metrics

Pressure BioSciences Revenue

Pressure BioSciences's revenue was reported to be $1.81 m in FY, 2019
USD

Revenue (Q3, 2020)

533.9k

Gross profit (Q3, 2020)

286.8k

Gross profit margin (Q3, 2020), %

53.7%

Net income (Q3, 2020)

(3.3m)

EBIT (Q3, 2020)

(818.8k)

Market capitalization (26-Feb-2021)

8.9m

Closing stock price (26-Feb-2021)

2.3

Cash (30-Sept-2020)

94.8k

EV

23.0m
Pressure BioSciences's current market capitalization is $8.9 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

987.7k1.2m1.5m1.4m1.8m2.0m2.2m2.5m1.8m

Revenue growth, %

10%

Cost of goods sold

609.1k834.0k1.3m1.3m1.2m

Gross profit

1.2m1.1m967.1k1.2m612.9k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

190.7k280.4k305.7k324.9k297.9k370.7k357.7k420.8k404.1k307.5k372.5k440.1k413.1k580.3k510.5k511.0k535.3k551.4k540.4k646.1k610.8k639.0k521.8k510.2k518.7k501.2k253.9k268.2k533.9k

Cost of goods sold

108.7k175.2k209.8k221.7k243.1k262.9k236.0k287.3k328.7k324.8k270.0k234.3k309.7k304.2k285.8k175.1k134.9k247.0k

Gross profit

189.2k237.9k370.5k288.8k267.9k272.4k315.4k253.1k317.3k286.0k369.0k287.4k200.5k214.5k215.4k78.7k133.3k286.8k

Gross profit Margin, %

64%58%64%57%52%51%57%47%49%47%58%55%39%41%43%31%50%54%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

222.8k1.5k31.4k473.9k116.8k138.4k81.0k103.1k29.6k

Accounts Receivable

269.2k216.3k147.6k272.0k113.3k206.8k474.8k229.4k

Prepaid Expenses

143.6k83.4k85.6k104.2k213.9k214.7k170.7k213.5k

Inventories

1.1m923.4k736.7k850.6k1.0m258.1k857.7k765.5k617.7k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

234.4k297.0k15.5k20.9k50.3k167.9k113.7k66.7k428.5k9.4k98.2k220.3k38.2k76.9k93.4k71.6k41.9k121.4k201.3k18.7k81.2k18.5k5.9k269.7k117.9k135.4k31.8k41.5k94.8k

Accounts Receivable

159.0k115.0k204.0k241.7k294.9k278.0k314.2k200.9k178.4k190.7k335.0k323.4k350.0k362.8k393.9k511.1k589.7k518.7k564.0k548.3k322.6k526.1k374.3k443.2k410.6k411.4k120.9k121.3k330.5k

Prepaid Expenses

80.4k128.3k269.8k374.6k510.4k103.7k53.4k61.0k229.0k157.6k120.1k127.0k151.5k74.4k337.5k145.0k180.0k207.7k175.9k146.3k199.3k202.7k254.5k183.3k127.7k239.2k203.9k192.6k159.7k

Inventories

1.1m1.1m1.0m975.9k905.7k890.9k866.6k851.5k786.8k853.2k852.5k799.0k783.9k808.8k966.5k1.0m1.0m940.4k1.1m1.1m892.4k900.1k899.9k753.1k744.8k713.9k655.8k614.9k516.2k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.0m)(3.5m)(4.1m)(4.6m)(7.4m)(2.7m)(10.7m)(9.7m)(11.7m)

Depreciation and Amortization

141.3k107.5k79.6k65.7k25.3k17.9k8.6k94.3k123.6k

Inventories

48.6k95.7k186.7k(113.9k)(187.8k)133.1k(112.0k)(56.1k)78.8k

Accounts Payable

763.8k309.2k(97.1k)(67.0k)(94.4k)(534.1k)182.0k69.6k156.9k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(1.6m)(2.2m)(1.1m)(1.6m)(2.4m)(779.4k)(1.8m)(2.5m)(1.8m)(2.4m)(3.3m)(2.0m)(2.8m)(3.4m)(6.0m)(5.0m)(5.9m)(5.6m)(6.2m)(7.9m)(2.2m)(4.5m)(6.3m)(2.1m)(4.8m)(8.0m)(4.0m)(8.5m)(11.8m)

Depreciation and Amortization

77.0k109.5k29.3k57.2k82.4k21.5k40.4k63.0k19.6k39.7k59.4k6.9k12.2k18.3k6.2k12.3k15.5k2.5k4.7k7.0k23.5k45.9k70.7k23.6k47.2k68.8k45.0k74.2k103.4k

Inventories

(29.8k)(4.1k)47.7k93.1k(163.4k)32.5k56.7k71.9k(50.1k)(116.5k)(115.8k)51.6k66.7k41.7k71.8k36.0k30.2k(35.1k)(226.2k)(217.5k)(14.8k)(2.5k)(2.4k)12.3k20.7k51.6k(38.1k)2.9k101.5k

Accounts Payable

276.5k537.2k238.8k304.9k399.1k(140.5k)(116.6k)1.9k(90.0k)59.3k(17.0k)(115.7k)(56.3k)(201.0k)(161.3k)(51.5k)(409.2k)265.5k338.8k445.9k51.8k108.7k16.4k(184.4k)152.3k838.3k54.5k(5.9k)(109.4k)
show all
USDQ2, 2011

Financial Leverage

4.5 x
Show all financial metrics

Pressure BioSciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

Learn more about our premium products
SecurityScorecard logo

Pressure BioSciences Online and Social Media Presence

Pressure BioSciences's Trends

Embed Graph

Pressure BioSciences News and Updates

February 08, 2021

Pressure BioSciences Plans to Acquire Assets of Global Eco-Friendly Agrochemical Supplier

SOUTH EASTON, Mass., Feb. 8, 2021 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology,...
December 15, 2020

Pressure BioSciences to Present at Upcoming Life Sciences Investor Forum

SOUTH EASTON, Mass., Dec. 15, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will participate in the Life Sciences Investor Forum ("LSIF") on Thursday December 17, 2020. LSIF is a live, interactive investor event...
December 04, 2020

Pressure BioSciences Proposed Acquisition Partner Cannaworx, Inc. Announces December 2020 Launch Date for FDA Registered Immune Booster

SOUTH EASTON, Mass., Dec. 4, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology,...
November 11, 2020

Pressure BioSciences Awarded First U.S. Patent for Revolutionary Ultra Shear Technology Platform

SOUTH EASTON, Mass., Nov. 11, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide life sciences and other...
August 12, 2020

Pressure BioSciences Awarded Pivotal U.S. Patent for Novel, High Pressure Enhanced Consumable Device

SOUTH EASTON, Mass., Aug. 12, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide Life Sciences and other...
December 30, 2019

Zacks Small Cap Research Releases Updated Report on Pressure BioSciences, Inc.

SOUTH EASTON, Mass., Dec. 30, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sci…
Show more

Pressure BioSciences Blogs

March 04, 2021

Transformative Impact for Food Industry Consortium Formed by Pressure BioSciences and The Ohio State University Discussed in Showcase Video from Emerging Technology Insider

Interview of PBIO CEO Ric Schumacher Focuses on Potential Impact of Company's Innovative UST Platform for Major Advances in Food Safety, Clean Label, Nutrition, and Long-Term Room Temperature Stability SOUTH EASTON, Mass., March 4, 2021 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("P…
February 24, 2021

Pressure BioSciences and The Ohio State University Announce Food Industry Consortium to Advance Commercialization of PBI's Ultra Shear Technology

Academia-Industry Partnership to Support Improvements in UST Applications and Allow Global Food Companies Access to UST for Preparation of Safer, More Nutritious Liquid Foods and Beverages SOUTH EASTON, Mass., Feb. 24, 2021 /PRNewswire/ --Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Co…
January 20, 2021

Pressure BioSciences Ultra Shear Technology Nanoemulsions Platform Targets Revolution in Effectiveness of Therapeutics via Improved Drug Delivery and Dosing Safety

PBI Announces Collaboration to Improve and Optimize SinuSys Corp's Lead Sinus Health Product Candidate for Commencement of Phase IIb Clinical Study SOUTH EASTON, Mass., Jan. 20, 2021 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and…
December 17, 2020

Pressure BioSciences PCT Platform at Forefront in Generating Pivotal Findings by Diverse COVID-19 Research Teams in USA, China, and Europe

PCT's Effectiveness and Reproducibility Impacts Research Results and Fills Critical Role in Achieving Important Insights for the Development of New and Improved COVID-19 Diagnostics and Therapeutics SOUTH EASTON, Mass., Dec. 17, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI"…
November 17, 2020

Pressure BioSciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

Instrument Sales Increase 68%, Total Revenue Increases 7%, Operating Loss Decreases 23% (Q/Q); Planned Release of Revolutionary UST System in Mid-2021 Expected to Drive Major Revenue Growth and Progression to Profitability Investor Conference Call Scheduled for Tuesday, November 17, 2020 at 4:30 PM …
November 16, 2020

Pressure BioSciences, Inc. to Discuss Third Quarter 2020 Financial Results and Provide Business Update

Conference Call Scheduled for Tuesday, November 17th at 4:30pm ET SOUTH EASTON, Mass., Nov. 16, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2020 financial results a…

 Pressure BioSciences Frequently Asked Questions

  • When was Pressure BioSciences founded?

    Pressure BioSciences was founded in 2004.

  • Who are Pressure BioSciences key executives?

    Pressure BioSciences's key executives are Richard T. Schumacher, Jeffrey N. Peterson and Edmund Ting.

  • How many employees does Pressure BioSciences have?

    Pressure BioSciences has 17 employees.

  • What is Pressure BioSciences revenue?

    Latest Pressure BioSciences annual revenue is $1.8 m.

  • What is Pressure BioSciences revenue per employee?

    Latest Pressure BioSciences revenue per employee is $106.5 k.

  • Who are Pressure BioSciences competitors?

    Competitors of Pressure BioSciences include REMSleep Holdings, ControlRad Systems and Cerevast Therapeutics.

  • Where is Pressure BioSciences headquarters?

    Pressure BioSciences headquarters is located at 14 Norfolk Ave, South Easton, Easton.

  • Where are Pressure BioSciences offices?

    Pressure BioSciences has offices in Easton and Medford.

  • How many offices does Pressure BioSciences have?

    Pressure BioSciences has 2 offices.